Polymerized Amyloid Peptides for Targeted Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic approaches for amyloid diseases, such as Alzheimer's, face challenges including potential cell-mediated toxicity, non-specific targeting of normal and amyloidogenic proteins, and poor efficacy, which hinder effective reduction of amyloid burden and cognitive benefits.
Innovation Solution
Development of non-amyloidogenic, non-fibrillogenic polymerized products comprising multiple protein or peptide units like Aβ, α-synuclein, tau, and prion proteins, and antibodies specific to these products to generate a targeted immunological response, overcoming the obstacles of existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional immunotherapy is used to reduce amyloid burden, then amyloid deposition is reduced, but cell-mediated toxicity and non-specific targeting occur
Solution Approach 1:
The patent modifies the immunogen structure to create local conformational epitopes that are specific to amyloidogenic conformations. The polymerized peptides are designed to present localized structural features (beta-sheet rich regions) that mimic the pathological conformation, enabling antibodies to target only the abnormal form while sparing normal proteins. This resolves the contradiction by making the immune response locally specific to the pathological conformation rather than globally targeting all forms of the protein.
Solution Approach 2:
The patent changes the physical-chemical parameters of the immunogen by polymerizing peptides to create high molecular weight complexes with specific conformational epitopes. This parameter change (from monomeric to polymeric form) transforms the immunogenic properties, enabling the generation of antibodies that recognize conformational rather than linear epitopes. This allows specific targeting of amyloidogenic conformations without cross-reactivity with normal proteins, resolving the toxicity issue.
2Quantity of substance
If conventional immunotherapy targets amyloid proteins, then amyloid burden is reduced, but normal and abnormal proteins are both targeted
Solution Approach 1:
The patent employs local quality by designing immunogens that present specific conformational epitopes found only in amyloidogenic proteins. The polymerized peptide structure creates localized beta-sheet rich regions that serve as conformational epitopes, enabling antibodies to distinguish between normal and abnormal protein forms based on their three-dimensional structure rather than linear sequence, thus achieving high specificity.
Solution Approach 2:
The patent uses polymerized peptides as an intermediary that bridges the gap between normal protein structure and amyloid fibril structure. These intermediates present conformational epitopes that are characteristic of the pathological state but not present in normal proteins, serving as a safe target for antibody generation. This intermediary approach allows the immune system to learn to recognize and target only the abnormal conformation without cross-reacting with normal proteins.
3Quantity of substance
If conventional immunotherapy is administered, then some amyloid reduction is achieved, but cognitive benefits are poor
Solution Approach 1:
The patent changes the molecular weight and conformational parameters of the immunogen by using polymerized peptides. This creates high molecular weight complexes that present multiple conformational epitopes, potentially generating a more robust and specific immune response. The altered physical parameters of the immunogen may improve antigen presentation and antibody generation, leading to better therapeutic outcomes that correlate with amyloid reduction.
Solution Approach 2:
The patent uses composite structures formed by polymerizing multiple peptide units together. These composite materials present multiple epitopes in a specific spatial arrangement, potentially generating a broader and more specific immune response. The composite nature of the immunogen (polymerized peptides with specific conformational features) may enhance its ability to elicit a therapeutic immune response that effectively reduces amyloid burden and improves cognitive function.
Data Source
AI summary
The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.